Influenza Virus Infection Market
Global Influenza Virus Infection Market Size, Share & Trends Analysis Report By Treatment (Baloxavir Marboxil and Oseltamivir Phosphate), By Influenza Type (Influenza A and Influenza B) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) Forecast Period (2022-2028)
The global influenza virus infection market is anticipated to grow at a significant CAGR of 5.2% during the forecast period. The increasing prevalence of influenza infection is acting as an important factor that is driving the growth of the market. Influenza is a virus that affects the respiratory system, which includes the nose, throat, and lungs. The influenza virus has been constantly spreading, and creating regional problems that have resulted in thousands of deaths. According to data from the Centres for Disease Control and Prevention (CDC), more than 13 million flu cases have been reported so far in 2019-20. So, during the forecasted period, the rising occurrence of influenza infection is expected to boost the demand for the product.
Impact of COVID-19 Pandemic on Global Influenza Virus Infection Market
The COVID-19 pandemic had an unavoidable impact on routine immunisation programs in both developing and developed countries around the globe. Flu vaccination rates, on the other hand, have increased significantly during the COVID-19 pandemic as a result of factors such as increased pressure from health experts & departments and the extension of various government programs that provide free flu immunisation. Furthermore, increasing public knowledge of the increased risk of contracting COVID-19 if the flu weakens the immune system is another factor contributing to flu vaccination adoption.
Segmental Outlook
The global influenza virus infection market is segmented based on treatment, influenza type and distribution channel. Based on the treatment, the market is sub-segmented into baloxavir marboxil and oseltamivir phosphate. Based on the influenza type, the market is sub-segmented into influenza A and influenza B. Based on the distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies and online pharmacies. Further, based on the treatment, the oseltamivir phosphate segment is expected to have a significant proportion in the influenza virus infection market, owing to one of the most widely prescribed medications for influenza therapy and its high treatment efficacy.
Global Influenza Virus Infection Market Share by Influenza Type, 2021 (%)
The Influenza A Segment Holds the Prominent Share in the Global Influenza Virus Infection Market
The influenza A segment holds a prominent market share and is anticipated to grow significantly during the forecast period in the global influenza virus infection market in the influenza type segment. This is mostly due to the rising prevalence of influenza A and the enormous number of patients infected with the virus around the globe. Apart from being the most common kind of influenza, another factor that contributes to its spread is its status as a life-threatening form of influenza. The influenza A strain of the disease has been attributed to a number of major influenza pandemics.
Regional Outlooks
The global Influenza virus infection market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Influenza Virus Infection Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Influenza Virus Infection Market
The Asia-Pacific region holds a significant share and is anticipated to grow prominently during the forecast period in the influenza virus infection market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall influenza market. There is an increasing awareness of influenza as a result of rising disposable income and government actions across the region. Additionally, the increasing prevalence of influenza in the main nations in the area and the increasing status of influenza as the top cause of mortality is also projected to boost the market expansion across the region.
Market Players Outlook
The major companies serving the global influenza virus infection market include Genentech, Inc., Shionogi & Co., Ltd., Seqirus, Biocryst Pharmaceutical, Inc., GlaxoSmithKline plc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2019, Genentech’s Xofluza (Baloxavir Marboxil) was approved by the FDA for people who are at a high risk of suffering influenza-related complications. Xofluza is a first-in-class, single-dose oral drug with a new mechanism of action that inhibits polymerase acidic endonuclease, a viral replication enzyme.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global influenza virus infection market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Influenza Virus Infection Market
- Recovery Scenario of Global Influenza Virus Infection Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. BIOCRYST PHARMACEUTICALS, INC.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Genentech, Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. GlaxoSmithKline plc.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. SHIONOGI & Co., Ltd.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Seqirus
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Influenza Virus Infection Market by Treatment
4.1.1. Baloxavir marboxil
4.1.2. Oseltamivir phosphate
4.2. Global Influenza Virus Infection Market by Influenza Type
4.2.1. Influenza A
4.2.2. Influenza B
4.3.Global Influenza Virus Infection Market by Distribution channel
4.3.1. Hospital pharmacies
4.3.2. Retail pharmacies
4.3.3 Online pharmacies
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott
6.2. Alvogen
6.3. Amneal Pharmaceuticals LLC
6.4. Autoimmune Technologies, LLC
6.5. ContraFect Corp.
6.6. Lupin Pharmaceuticals, Inc.
6.7. Macleods Pharmaceuticals Ltd.
6.8. Teva Pharmaceutical Industries Ltd.
6.9. Vir Biotechnology, Inc.
6.10. Zydus Pharmaceuticals, Inc.
1. GLOBAL INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
2. GLOBAL BALOXAVIR MARBOXIL INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL OSELTAMIVIR PHOSPHATE INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY INFLUENZA TYPE, 2021-2028 ($ MILLION)
5. GLOBAL INFLUENZA A VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL INFLUENZA B VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
8. GLOBAL HOSPITAL PHARMACIES INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL RETAIL PHARMACIES INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ONLINE PHARMACIES INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
14. NORTH AMERICAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY INFLUENZA TYPE, 2021-2028 ($ MILLION)
15. NORTH AMERICAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
16. EUROPEAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
18. EUROPEAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY INFLUENZA TYPE, 2021-2028 ($ MILLION)
19. EUROPEAN INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY INFLUENZA TYPE, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
24. REST OF THE WORLD INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. REST OF THE WORLD INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
26. REST OF THE WORLD INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY INFLUENZA TYPE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD INFLUENZA VIRUS INFECTION MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL INFLUENZA VIRUS INFECTION MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL INFLUENZA VIRUS INFECTION MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL INFLUENZA VIRUS INFECTION MARKET, 2022-2028 (%)
4. GLOBAL INFLUENZA VIRUS INFECTION MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
5. GLOBAL BALOXAVIR MARBOXIL INFLUENZA VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL OSELTAMIVIR PHOSPHATE INFLUENZA VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL INFLUENZA VIRUS INFECTION MARKET SHARE BY INFLUENZA TYPE, 2021 VS 2028 (%)
8. GLOBAL INFLUENZA A VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL INFLUENZA B VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL INFLUENZA VIRUS INFECTION MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
11. GLOBAL HOSPITAL PHARMACIES INFLUENZA VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL RETAIL PHARMACIES INFLUENZA VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL ONLINE PHARMACIES INFLUENZA VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL INFLUENZA VIRUS INFECTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
17. UK INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD INFLUENZA VIRUS INFECTION MARKET SIZE, 2021-2028 ($ MILLION)
